|
Title
|
|
|
|
Telaprevir : efficacy and safety
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Standard of care treatment of chronic hepatitis C genotype 1 virus infection with pegylated interferon and ribavirin has been associated with rates of treatment success of only 50%. Telaprevir is one of the first NS3/4A protease inhibitors which, in combination with pegylated interferon and ribavirin, leads to higher rates of sustained viral response. Telaprevir has been approved for treatment-naïve and experienced patients with chronic HCV genotype 1 infection. Current clinical limitations include high rates of adverse events, long treatment duration and unclear use in special populations such as transplant patients and HIV coinfected patients. Future research will need to clarify these clinical obstacles and look for other treatment options. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal of symptoms and signs
| |
|
Publication
|
|
|
|
2014
| |
|
Volume/pages
|
|
|
|
3
:1
(2014)
, p. 16-25
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|